### The Role of Glomerular Filtration Rate (GFR) for Treatment with Peginterferon alfa-2A (40KD) and Ribavirin in Patients with Chronic Hepatitis C (CHC)

Zehnter E1, Mauss S2, K Boeker K3, Lutz T4, Racky S5, Schmidt W6, Ulrich R7, Sbrijer I8, Heyne R9, Schober A10, John C11, Hey KH12, Bokemeyer B1, Kalinowski B1, Moeller B2, Sape S5, Alshuth U1, Hueppe D1

1Center of Gastroenterology, Dortmund; 2Center for HIV and Hepatogastroenterology, Düsseldorf; 3Center of Gastroenterology, Hannover; 4Center of Infectiology and Hepatology, Frankfurt; 5Center of Gastroenterology, Krefeld; 6Center of Gastroenterology and Livercenter, Berlin; 7Center of Gastroenterology, Göttingen; 8Center of Gastroenterology, Berlin; 9Center of Gastroenterology, Paderborn; 10Center of Gastroenterology, Schwetzingen; 11Center of Gastroenterology, Paderborn; 12Roche Pharma AG, Grenzach-Wyhlen; 13Center of Gastroenterology, Herne

---

### INTRODUCTION

- Concerning importance of sufficient application of Ribavirin (RBV) the question was raised several times in the past whether dosing according to glomerular filtration rate (GFR) would be more optimal than to body weight.
- The “Association of German Independent Gastroenterologists” (Bing, Berufsverband Niedergelassener Gastroenterologen Deutschlands e.V.) in cooperation with Roche, Germany, is conducting a nationwide observational study including screening and treatment phases to determine the quality of treatment for chronic hepatitis C (CHC) in routine clinical practice.

### OBJECTIVE

- The aim of this observational study was to evaluate the influence of GFR in connection with standardised Ribavirin doses on sustained virological response (SVR), tolerability and Ribavirin dose-adjustment in everyday practice.

### METHODS

- This evaluation is part of a large ongoing German multicentre, open-label observational study including anti-HCV-positive adults with detectable HCV RNA. The nature of this study allowed dosing and duration of both peginterferon alfa-2a (40KD) and Ribavirin to be at the discretion of the physician.
- The screening data include age, sex, weight, height, duration and source of infection, prior antiviral treatment, clinical symptoms, histology, genotype, viral load, concomitant diseases and social status.
- This data set includes treatment naive patients who initiated treatment with peginterferon alfa-2a (40KD) plus ribavirin. The data collection was performed online via the internet. The documented data should reflect the clinical routine as intended by the doctors in charge. Therefore, the statistical analysis remains descriptive.
- Due to the matching characteristics of the study, the status of data was frozen on May 31st, 2006, including queries solved.
- To analyse GFR (in ml/min/1,73m²) the method of Mayo Clinic (Rule AD et al., Ann. Intern Med. 2004) was used according to KDOQI-categorisation.

### RESULTS

#### Patients

- A total of 10326 treatment naïve patient screenings (see Figure 1) have been completed and 4377 of these patients (42.4%) have been treated with peginterferon alfa-2a (40KD), almost in all cases plus ribavirin.
- In 3111/4377 patients treatment documentation was completed.
- In 1615/3111 patients a complete data set including GFR, BMI, weight, and height were available.

#### Baseline data

- Baseline data of both groups were: male sex 62.1% in NORMAL vs. 57.3% in LOW-RENAL, age (yrs) 40.1 in NORMAL vs. 41.7 in LOW-RENAL, weight (mean ± SD in kg) 74.9 ± 15.0 in NORMAL vs. 72.1 ± 13.2 in LOW-RENAL (see Table 1).

#### Virological response

- Sustained virological response (SVR; HCV RNA undetectable) differs from 41.1% (N=44/107) in LOW-RENAL to 66.7% (N=920/1498) in NORMAL.

#### Safety

- The rate of discontinuation was 20.7% in NORMAL vs. 29.0% in LOW-RENAL.
- Concerning special side effects of Ribavirin, anaemia was more frequent in LOW-RENAL (35.5%) than in NORMAL (16.1%) (see Figure 2).
- The same trend was found for skin alterations (NORMAL 18.4%, LOW-RENAL 27.1%) but for cough (see Figure 4).

#### Ribavirin

- The mean initial dose of Ribavirin was 954.7 mg/d in NORMAL and 988.8 mg/d in LOW-RENAL (see Figure 5).

### CONCLUSIONS

- Renal function measured by GFR plays an important role in achieving SVR. Distinct differences were found in genotype, age and sex but not in BMI and weight between patients with GFR >90 in NORMAL and patients with GFR >60 in LOW-RENAL.
- Since weight based dosing of Ribavirin does not consider these facts, patients with constricted renal function suffer more side effects and get worse SVR rates maybe due to non-optimal Ribavirin dosing.
- A need for optimal RBV dosing is evident in LOW-RENAL GT1/4-patients with low SVR and high AE rates. Lower cumulative RBV-doses following comparable initial doses of RBV indicate dose reductions of RBV during treatment. It may be discussed, if a dose adjustment of RBV acc. to renal function would have optimised treatment success.

---

### Table 1: Baseline data

<table>
<thead>
<tr>
<th></th>
<th>NORMAL (GFR &gt; 90)</th>
<th>LOW-RENAL</th>
<th>GFR &gt;60</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>N=1498</td>
<td>N=107</td>
<td>N=10</td>
<td>N=1615</td>
</tr>
<tr>
<td>Sex (male / female)</td>
<td>62.1% / 38.9%</td>
<td>30.0% / 70.0%</td>
<td>60.0% / 40.0%</td>
<td>60.0% / 40.0%</td>
</tr>
<tr>
<td>Age (mean ± SD in years)</td>
<td>40.1 ± 11.3</td>
<td>57.3 ± 13.1</td>
<td>44.9 ± 11.7</td>
<td>41.3 ± 12.2</td>
</tr>
<tr>
<td>Weight (mean ± SD in kg)</td>
<td>74.9 ± 15.0</td>
<td>72.1 ± 13.2</td>
<td>69.8 ± 9.9</td>
<td>74.7 ± 14.9</td>
</tr>
<tr>
<td>BMI (mean ± SD in kg/m²)</td>
<td>24.9 ± 4.3</td>
<td>25.8 ± 4.5</td>
<td>24.3 ± 3.5</td>
<td>24.9 ± 4.3</td>
</tr>
<tr>
<td>Duration of infection (years)</td>
<td>11.0 ± 8.4</td>
<td>16.7 ± 11.3</td>
<td>7.3 ± 9.9</td>
<td>11.4 ± 8.8</td>
</tr>
</tbody>
</table>

* Glomerular Filtration Rate in ml/min/1,73m²

---

*Presented at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), April 11-15, 2007, Barcelona, Spain. This research was funded by Roche Pharma AG, Grenzach-Wyhlen, Germany.*